XALKORI (CRIZOTINIB) approved for ALK-POSITIVE anaplastic large cell LYMPHOMA in children and young adults
19 Gennaio 2021
The FDA has approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric patients 1 year of age and older and
